Medications Updated During May 2011, From Newest to Oldest, Page 3

Page 3 of 19 « 1 2 3 4 5 … 10 15 … » Last Page »

Mirtazapine

Mirtazapine tablets are indicated for the treatment of major depressive disorder. The efficacy of mirtazapine in the treatment of major depressive disorder was established in 6 week controlled trials of outpatients whose diagnoses corresponded most…

KAISER FOUNDATION HOSPITALS24 May 2011

Cyclobenzaprine Hydrochloride

Cyclobenzaprine hydrochloride extended-release capsules is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm…

Global Pharmaceuticals, Division of Impax Laboratories Inc.23 May 2011

OKT3 (Muromonab-CD3)

ORTHOCLONE OKT3 is indicated for the treatment of acute allograft rejection in renal transplant patients. ORTHOCLONE OKT3 is indicated for the treatment of steroid-resistant acute allograft rejection in cardiac and hepatic transplant patients. The…

Centocor Ortho Biotech Products, L.P.23 May 2011

Animi-3 with Vitamin D (Folic Acid, Cholecalciferol, Pyridoxine Hydrochloride, Cyanocobalamin, Omega-3 Fatty Acids, Doconexent, Icosapent)

Animi-3 with Vitamin D Capsules are indicated for improving nutritional status in conditions requiring Essential Fatty Acids. Vitamin B12. Vitamin B6. Vitamin D3 and Folic Acid supplementation. This product is contraindicated in patients with a…

PBM Pharmaceuticals, Inc23 May 2011

ENDODAN (OXYCODONE and ASPIRIN)

ENDODAN tablets are indicated for the management of moderate to moderately severe pain. CONTRAINDICATIONS: ENDODAN tablets are contraindicated in patients with known hypersensitivity to oxycodone or aspirin, and in any situation where opioids or…

STAT RX USA LLC23 May 2011

Page 3 of 19 « 1 2 3 4 5 … 10 15 … » Last Page »

FDA Medwatch

CME America Announces a Follow-Up on the Voluntary Recall of BodyGuard® Infusion System Administration Sets
Tue, 07 Jul 2020. As part of CME America's commitment to quality, following the previously announced recall (April 27, 2020) of the BodyGuard® Infusion Pump Systems, the company conducted additional flow-rate accuracy testing. This testing revealed that some…
Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets, 500mg and 1000mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
Tue, 07 Jul 2020. Lupin Pharmaceuticals Inc. is voluntarily recalling all batches of Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg to the consumer level. As part of the ongoing assessment and continuation of the dialog with the FDA,…

MedLibrary.org

Medication Sections

RSS Feeds

About

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.